PROPRIETARY PROTEIN CRYSTALS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 SGX是一家结构导向的药物发现公司，加速发现治疗人类疾病的新疗法。新加坡证券交易所开发了FAST(活性结构片段)，这是一项专有技术，用于快速识别新型、有效和选择性的药物靶标小分子抑制剂。FAST依赖于SGX开发的合成使能片段库，以确保快速实现从点击到领先的优化，并利用SGX的高通量X射线共结晶学、最先进的计算评分和自动并行合成。 SGX技术通过迭代确定共晶体结构，以原子细节揭示小分子如何与药物靶标相互作用，从而推动铅优化过程。SGX利用FAST“a”开展专注于肿瘤学的项目以及其他疾病领域的合作项目。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SGX is a structure guided drug discovery company accelerating the discovery of novel therapeutics to treat human diseases. SGX has developed FAST¿¿¿¿¿a"¿¿¿ (Fragments of Active Structures), a proprietary technology for rapid identification of novel, potent and selective small molecule inhibitors of drug targets. FAST¿¿¿¿¿a"¿¿¿ relies on libraries of synthetically enabled fragments developed by SGX, to ensure rapid hit-to-lead optimization and draws on SGX high-throughput X-ray co-crystallography, state of the art computational scoring and automated parallel synthesis. SGX technology drives the lead optimization process through iterative determination of co-crystal structures that reveal, in atomic detail, how small molecules interact with drug targets. SGX leverages FAST¿¿¿¿¿a"¿¿¿ for programs focused in oncology as well as partnered programs in other disease areas.